Laboratorios Farmaceuticos ROVI - Asset Resilience Ratio

Latest as of June 2025: 0.17%

Laboratorios Farmaceuticos ROVI (ROVI) has an Asset Resilience Ratio of 0.17% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ROVI current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€1.51 Million

≈ $1.76 Million USD Cash + Short-term Investments

Total Assets

€869.61 Million

≈ $1.02 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2004–2024)

This chart shows how Laboratorios Farmaceuticos ROVI's Asset Resilience Ratio has changed over time. See Laboratorios Farmaceuticos ROVI shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Laboratorios Farmaceuticos ROVI's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Laboratorios Farmaceuticos ROVI market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€1.51 Million	0.17%
Total Liquid Assets	€1.51 Million	0.17%

Asset Resilience Insights

Limited Liquidity: Laboratorios Farmaceuticos ROVI maintains only 0.17% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Laboratorios Farmaceuticos ROVI Industry Peers by Asset Resilience Ratio

Compare Laboratorios Farmaceuticos ROVI's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Regencell Bioscience Holdings Ltd NASDAQ:RGC	Drug Manufacturers - Specialty & Generic	43.05%
Changchun High & New Technology Industries Group Inc SHE:000661	Drug Manufacturers - Specialty & Generic	3.73%
Yuhan Corp. KO:000100	Drug Manufacturers - Specialty & Generic	0.99%
Tonghua Dongbao Pharmaceutical Co Ltd SHG:600867	Drug Manufacturers - Specialty & Generic	1.96%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Guobang Pharma Ltd SHG:605507	Drug Manufacturers - Specialty & Generic	8.47%

Annual Asset Resilience Ratio for Laboratorios Farmaceuticos ROVI (2004–2024)

The table below shows the annual Asset Resilience Ratio data for Laboratorios Farmaceuticos ROVI.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.03%	€227.00K ≈ $265.39K	€832.02 Million ≈ $972.72 Million	+0.04pp
2023-12-31	-0.01%	€-65.00K ≈ $-75.99K	€799.88 Million ≈ $935.15 Million	-5.06pp
2022-12-31	5.05%	€44.36 Million ≈ $51.86 Million	€878.70 Million ≈ $1.03 Billion	+5.06pp
2021-12-31	-0.01%	€-65.00K ≈ $-75.99K	€732.68 Million ≈ $856.58 Million	+0.00pp
2020-12-31	-0.01%	€-65.00K ≈ $-75.99K	€574.44 Million ≈ $671.58 Million	+0.00pp
2019-12-31	-0.01%	€-65.00K ≈ $-75.99K	€511.21 Million ≈ $597.66 Million	+0.00pp
2018-12-31	-0.02%	€-65.00K ≈ $-75.99K	€402.70 Million ≈ $470.80 Million	+0.01pp
2017-12-31	-0.02%	€-65.00K ≈ $-75.99K	€298.38 Million ≈ $348.84 Million	-0.03pp
2016-12-31	0.01%	€32.00K ≈ $37.41K	€287.85 Million ≈ $336.52 Million	-0.01pp
2015-12-31	0.02%	€61.00K ≈ $71.32K	€263.85 Million ≈ $308.46 Million	-0.44pp
2014-12-31	0.47%	€1.22 Million ≈ $1.43 Million	€261.32 Million ≈ $305.51 Million	-0.05pp
2013-12-31	0.52%	€1.22 Million ≈ $1.43 Million	€235.92 Million ≈ $275.82 Million	+0.02pp
2012-12-31	0.50%	€1.12 Million ≈ $1.31 Million	€222.36 Million ≈ $259.97 Million	-2.13pp
2011-12-31	2.63%	€6.00 Million ≈ $7.01 Million	€228.07 Million ≈ $266.64 Million	-9.62pp
2010-12-31	12.25%	€26.08 Million ≈ $30.49 Million	€212.89 Million ≈ $248.89 Million	+12.25pp
2009-12-31	0.00%	€2.00K ≈ $2.34K	€165.91 Million ≈ $193.97 Million	-0.06pp
2008-12-31	0.06%	€72.00K ≈ $84.18K	€120.55 Million ≈ $140.93 Million	-2.42pp
2007-12-31	2.48%	€2.78 Million ≈ $3.25 Million	€112.16 Million ≈ $131.13 Million	+2.12pp
2006-12-31	0.36%	€275.00K ≈ $321.50K	€76.04 Million ≈ $88.90 Million	+0.36pp
2005-12-31	0.00%	€3.11 Million ≈ $3.63 Million	€8.15 Trillion ≈ $9.53 Trillion	-0.16pp
2004-12-31	0.16%	€12.72 Million ≈ $14.87 Million	€7.88 Billion ≈ $9.21 Billion	--

pp = percentage points

About Laboratorios Farmaceuticos ROVI

MC:ROVI Spain Drug Manufacturers - Specialty & Generic

Market Cap

$4.75 Billion

€4.06 Billion EUR

Market Cap Rank

#4275 Global

#34 in Spain

Share Price

€79.40

Change (1 day)

+0.95%

52-Week Range

€51.35 - €85.55

All Time High

€90.54